Pertuzumab Plus Trastuzumab for Treatment-Refractory HER2-Amplified Metastatic Colorectal Cancer: Comparison of the MyPathway Trial With a Real-World External Control Arm The smart functionality of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback